A Phase I, Open-Label, Two-Arm Study of MP-424 [telaprevir] in Combination With Peginterferon Alfa 2b and Ribavirin in Patients With Genotype 1b Hepatitis C

Trial Profile

A Phase I, Open-Label, Two-Arm Study of MP-424 [telaprevir] in Combination With Peginterferon Alfa 2b and Ribavirin in Patients With Genotype 1b Hepatitis C

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2014

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 17 Jan 2013 Actual initiation date changed from Jan 2008 to Apr 2008 as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top